Mystic, CT, United States of America

Xianyang Qiu


Average Co-Inventor Count = 8.0

ph-index = 2

Forward Citations = 15(Granted Patents)


Company Filing History:


Years Active: 2007-2010

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovations of Xianyang Qiu in Cancer Treatment

Introduction

Xianyang Qiu is a notable inventor based in Mystic, CT, who has made significant contributions to the field of cancer treatment. With a total of two patents to his name, Qiu's work focuses on the innovative use of human interleukin-18 (IL-18) polypeptides in therapeutic applications.

Latest Patents

Qiu's latest patents include a method of treating cancer by administering conjugates comprising human IL-18 and substitution mutants thereof. This method involves the use of human IL-18 polypeptides that are conjugated to water-soluble polymers at specific sites on the protein. The conjugates retain biological activity and demonstrate enhanced properties compared to unconjugated cytokines. Another patent details the conjugation of human IL-18 and its substitution mutants to water-soluble polymers, further emphasizing the innovative approach to cancer treatment.

Career Highlights

Throughout his career, Xianyang Qiu has worked with prominent companies such as SmithKline Beecham Corporation and GlaxoSmithKline LLC. His experience in these organizations has contributed to his expertise in the field of biotechnology and cancer research.

Collaborations

Qiu has collaborated with notable colleagues, including Narendra B Bam and Jacob Bongers, which has further enriched his research and development efforts.

Conclusion

Xianyang Qiu's innovative work in the field of cancer treatment through the use of human IL-18 polypeptides showcases his dedication to advancing medical science. His contributions are significant in the ongoing fight against cancer, and his patents reflect a promising future for therapeutic applications.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…